BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.

(1) Background: Individuals with BRCA1/2 gene mutations are at increased risk of breast and ovarian cancer. The prevalence of BRCA1/2 mutations varies by race and ethnicity, and the prevalence and the risks associated with most BRCA1/2 mutations has not been unknown in the Vietnamese population. We herein screen the entire BRCA1 and BRCA2 genes for breast and ovarian cancer patients with a family history of breast cancer and ovarian cancer, thereby, suggesting a risk score associated with carrier status and history for aiding personalized treatment; (2)
Methods: Between December 2017 and December 2019, Vietnamese patients who had a pathological diagnosis of breast and epithelial ovarian cancer were followed up, prospectively, after treatment from two large institutions in Vietnam. Blood samples from 33 Vietnamese patients with hereditary breast and ovarian cancers (HBOC) syndrome were collected and analyzed using Next Generation Sequencing; (3)
Results: Eleven types of mutations in both BRCA1 (in nine patients) and BRCA2 (in three patients) were detected, two of which (BRCA1:p.Tyr1666Ter and BRCA2:p.Ser1341Ter) have not been previously documented in the literature. Seven out of 19 patient's relatives had BRCA1/2 gene mutations. All selected patients were counselled about the likelihood of cancer rising and prophylactic screening and procedures. The study established a risk score associated with the cohorts based on carrier status and family history; (4) Conclusions: Our findings suggested the implications for the planning of a screening programme for BRCA1 and BRCA2 genes testing in breast and ovarian cancer patients and genetic screening in their relatives. BRCA1/2 mutation carriers without cancer should have early and regular cancer screening, and prophylactic measures. This study could be beneficial for a diverse group in a large population-specific cohort, related to HBOC Syndrome.

1. Introduction

Among the malignancies in women, breast and ovarian cancers account for a high proportion of new cases and deaths. In a recent update on the global cancer burden, using the GLOBOCAN 2020, 2.3 million women with breast cancer and 3000 women with ovarian cancer were diagnosed in 2020 [1]. Vietnam, a lower middle-income country with over 97 million people, has one of the lowest age-standardized incidence rates for breast and ovarian cancer. The incidence rates of breast cancer is calculated to be 34.2 cases per 100,000 population per year, and of ovarian cancer is 2.4 per 100,000 population per year [1]. To the best of our knowledge, there is no effective screening method or national screening programme for ovarian cancers in Vietnam, therefore the identification of high-risk subjects of ovarian cancer for prevention and timely treatment is meaningful and necessary. One of the risk factors for breast and ovarian cancers is mutations of breast cancer susceptibility genes, which were known to be BRCA1 and BRCA2—the dynamic regulators of genomic integrity. BRCA1 and BRCA2 inherited gene mutations, which greatly increase the risk of developing breast and ovarian cancers, are mutations that are frequently observed in hereditary breast and ovarian cancers (HBOC).

The detection of BRCA1/2 mutations benefits both patients with HBOC and their family members. Patients benefit from platinum based chemotherapy and targeted treatment with Poly (ADP-ribose) polymerase (PARP) inhibitors [2], while unaffected family members may benefit from genetic counseling for HBOC, thereby obtaining timely screening and reducing surgery such as prophylactic mastectomy or salpingo-oophorectomy [3]. Although two studies of BRCA1/2 gene mutations in the Vietnamese population were reported solely on patients themselves or in breast cancer [4,5], there have been no evidence on the mutations of these genes in HBOC patients. To date, there has been no official practice guideline for the diagnosis of HBOC syndrome in Vietnam; however, available national guidelines for the treatment of breast and ovarian cancer recommend target therapy for these patients with BRCA1/2 gene mutations. To better understand the prevalence of the mutations in BRCA1 and BRCA2 genes among those with HBOC syndrome, this study was conducted to screen entire BRCA1 and BRCA2 genes for breast and ovarian cancer patients with a family history of breast cancer and ovarian cancer, thereby suggesting a risk score associated with carrier status and history for aiding personalized treatment.

2. Materials and Methods

2.1. Patients and Sample Collection

Between December 2017 and December 2019, Vietnamese patients who had a pathological diagnosis of breast and epithelial ovarian cancer were followed up, prospectively, after treatment at the National Hospital of Obstetrics and Gynecology (NHOG), and National Cancer Hospital. Family history and clinical data (gender, birthplace, age at cancer diagnosis, tumor type, immunohistochemistry and histology data) of the patients were obtained from medical records. Of them, 33 eligible patients met one of two indicated criteria for HBOC genetic analysis of (i) breast and ovarian cancer in the same individual diagnosed at any age, and/or (ii) two or more breast/ovarian cancer cases diagnosed in family members.

Prior to the collection of blood samples and clinical data from all participants, all probands and their family members were counselled to fulfill informed consent to participate in the study, as required by the Vietnam Medical Ethics Council. All genetic analyses were performed at the Center for Gene-Protein Research, Hanoi Medical University (Hanoi, Vietnam).

Samples of 2 mL peripheral blood with EDTA anticoagulation were collected from the patients. Genomic DNA was extracted from peripheral blood samples using a commercial kit (Magjet Whole blood DNA Kit, Thermo Scientific, Dreieich, Germany) in strict accordance with the manufacturer’s instructions.

2.2. Genetic Testing

Regarding BRCA sequencing, Next Generation Sequencing was the method of choice to sequence and the entire coding region of both genes was covered for all probands.

Genomic DNA was used for library creation using the Ultra II FS library preparation kit (New England Biolabs, Ipswich, MA, USA). PCR products from the library creation step were hybridized with a mixture of probes specific for both entire coding regions of BRCA1 and BRCA2 genes with biotin binding. Dynabeads MyOne Streptavidin T1 Beads, supplied by Thermo Fisher, were used to capture the DNA fragmentations based on streptavidin-biotin interaction, according to the instructions of the xGen library hybridization kit (IDTDNA, Coralville, IA, USA). The captured DNA fragments were cloned for the second time by PCR to reach the required concentration for next-generation sequencing (10 nM). Then, fragments were denatured and sequenced using the Nextseq 500/550 High Output kit on the NextSeq 550 system (Illumina, San Diego, CA, USA).

Next-generation sequencing resulted in millions of DNA sequence pairs with the size of 75 nucleotides. Raw sequence data analysis, including BaseCalling, demultiplexing, and alignment to the standard human genome of the National Center for Biotechnology Information (NCBI), was performed using the Genome Analysis Toolkit (GATK) version 4.1. The entire software was written based on the optimization analysis method by the Broad Institute of Harvard and MIT, USA [6]. The analysis results recorded genetic variations of BRCA1 and BRCA2 genes in selected patients.

Sequence variants were described according to the Human Genome Variation Society (HGVS) nomenclature guidelines. Variants were confirmed using Sanger sequencing, with the BigDye Terminator v3.1 Cycle Sequencing Kit and the ABI PRISM 3500 Genetic Analyzer.

Common polymorphisms represented 5% of the general population, and variants of uncertain significance (VUS) or pathogenic variants were then classified referring to the following databases: Breast Cancer Information Core BIC (https://research.nhgri.nih.gov/; accessed date: 7 July 2021), Clinical Variants (https://www.ncbi.nlm.nih.gov/pubmed; accessed date: 8 July 2021), Leiden Open (source) Variation Database (LOVD) (http://www.lovd.nl/3.0/home; accessed date: 8 July 2021), as well as population databases and data from clinicians, clinical laboratories, and researchers worldwide.

2.3. Statistical Analysis

2.3.1. Survival Analysis for Breast Cancer and Ovarian Cancer Patients

Model fitting was performed using survival analysis of breast and ovarian cancer occurrences in the combined set of families. Individuals were censored at the age of occurrence in breast cancer and ovarian cancer. The model was adjusted to the mean observed age, with a distribution of the predictions around this age. Therefore, a subtraction was needed to obtain the estimated starting age of the study. We calculated interval censoring by subtracting cancer occurrence age by 30 without losing the generality [7,8,9].

2.3.2. Breast and Ovarian Risk Prediction

We calculated a risk score based on the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) [10,11]. The breast cancer incidence for individual ith at age was assumed to be birth-cohort specific, and to depend on the underlying BRCA1 or BRCA2 genotype and polygenotype through a model of the form. where for noncarriers, BRCA1 and BRCA2 carriers, respectively. is a polygenic component, assumed to be normally distributed with a mean of and variance of and independent of age. The baseline incidence rates are chosen so that the overall age-specific incidence for both diseases, averaged over all genotypes, is constrained to agree with population incidence rates for England and Wales over the period 1983–1987 (Antoniou et al., 2002, Antoniou et al., 2004) [12,13]. Ovarian and breast cancer risks are assumed to be independent from given genotype. In this paper, we computed the probability that a woman of a given age years developed breast or ovarian cancer by age , given the known family history (FH). For example, if we denote the event of breast cancer by and the event of being unaffected by , a generalized model can be formed as:

The risks can be computed as the ratio of the likelihood of observing the pedigree, with the individual being unaffected at age to the likelihood of observing mutated genes in the family. is the breast cancer incidence at age , and and are the probabilities of remaining free of breast and ovarian cancer respectively by age . The probability was estimated based on the density of the incident rate given carrier status (e.g., z-score).

2.3.3. Breast Cancer Familial Relative Risks

To estimate the polygenic effect ( in Equation (1)), it was assumed to be normally distributed with mean zero and variance . We also incorporated into an age-specific familial relative risks (FRRs), polygenic effect, and carrier status for an individual with an affected family member (FM), such as mother, daughter, aunt and/or grandmother, which was predicted according to the below equation.

3. Results

3.1. Detection of BRCA1 and BRCA2 Variants

A total of 33 women with HBOC syndrome were enrolled in this study. The mean age of the patients at diagnosis was 53.55 years (interquartile range, 34 to 80). Duplex cancer was present in six patients, 25 patients had only one type of cancer but had relatives diagnosed with ovarian/breast cancer, and two had both factors (Table 1).

Table 1

Patients with hereditary breast and ovarian cancer syndrome.

Characteristics	Patients with BRCA1/2 Mutations			Non-MutationPatient	Total
	BRCA1Mutation Patient	BRCA2Mutation Patient	Total
	N = 9 (27.3%)	N = 3 (9.1%)	N = 12 (36.4%)	N = 21 (64.6%)	N = 33 (100%)
Mean of diagnosed age (years)	48.0	61.0	51.25	54.86	53.55
HBOC
FH (OC and/or BC) only	8	1	9	16	25
Duplex cancer only	0	2	2	4	6
Both (FH & Duplex cancer)	1	0	1	1	2

FH: family history for breast and/or ovarian cancer; BC: previous breast cancer history; OC: ovarian cancer.

The BRCA1 and BRCA2 panel used in this study covers all targeted coding exons and exon-intron boundaries. Eleven mutations in BRCA1 and BRCA2 genes were detected in 12 patients (36.4%), containing 8 BRCA1 and 3 BRCA2 pathogenic variants (Table 2) [14,15,16,17,18,19,20,21,22]. The BRCA1:c.4997dupA mutation was found in two patients. BRCA1:c.4997dupA and BRCA2:c.4022delC were detected for the first time in the current study.

Table 2

List of BRCA1/2 genes variants.

No.	HGVS cDNA	HGVS Protein	Local	BCCR/OCCR	Domain/Binding	Type	Sign.	Ref.
01	c.1016delA	p.Lys339ArgfsTer2	BRCA1-Exon 11	−	−	F	P	[13]
02	c.1621C > T	p.Gln541Ter	BRCA1-Exon 11	OCCR1	−	N	P	[14]
03	c.2760_2763delACAG	p.Thr922LeufsTer77	BRCA1-Exon 11	OCCR3	−	F	P	[15]
04	c.4986 + 4A > T	IVS16+4A > T	BRCA1-Intron 16	BCCR23	BRCT/BACH1	Ss	P	[16]
05	c.4997dupA	p.Tyr1666Ter	BRCA1-Exon 17	BCCR23	BRCT/BACH1	N	P	CS
06	c.5068A > C	p.Lys1690Gln	BRCA1-Exon 17	BCCR23	BRCT/BACH1	M	VUS	[17]
07	c.5251C > T	p.Arg1751Ter	BRCA1-Exon 20	−	−	N	P	[18]
08	c.5335delC	p.Gln1779AsnfsTer14	BRCA1-Exon 22	BCCR23	BRCT/BACH1	F	P	[19]
09	c.4022delC	p.Ser1341Ter	BRCA2-Exon 11	OCCR1	−	N	P	CS
10	c.4478_4481delAAAG	p.Glu1493ValfsTer10	BRCA2-Exon 11	OCCR1	−	F	P	[20]
11	c.5453C > A	p.Ser1818Ter	BRCA2-Exon 11	OCCR1	−	N	P	[21]

OCCR: ovarian cancer cluster region; BCCR: breast cancer cluster region; F: frameshift; N: nonsense; M: missense; Ss: splice site; (−): absent; P: pathogenic; VUS: variant uncertain significance; CS: current study.

Eight mutations in the BRCA1 gene comprised of three nonsense mutations (c.1621C > T, c.4997dupA, and c.5251C > T), three frameshift mutations (c.1016delA, c.2760_2763delACAG and c.5335delC), one missense mutation (c.5068A > C) and one splice site mutation in intron 16 (c.4986 + 4A > T).

In which, two mutations (c.1621C > T and c.2760_2763delACAG) located in an ovarian cancer cluster region (OCCR), four mutations (c.4986 + 4A > T, c.4997dupA, c.5068A > C and c.5335delC) in a breast cancer cluster region (BCCR). All BCCR mutations were located in the BRCT domain, which was the BACH1 binding site (Figure 1).

Figure 1

The location of the variants in the BRCA1 gene.

Three mutations in the BRCA2 gene included two nonsense mutations (c.4022delC and c.5453C > A) and one frameshift mutation (c.4478_4481delAAAG). All of these mutations were located in exon 11 of the OCCR, or BRC repeat region, which was the binding site of protein RAD51 (Figure 2).

Figure 2

The location of the variants in the BRCA2 gene.

Blood samples from the family members of the 19 women who had BRCA1/2 mutations were collected in order to perform a genetic test. Seven of them (36.8%) were found to have BRCA1/2 gene mutations. A pedigree chart is shown in Figure 3.

Figure 3

Pedigree and sequencing results of the family with mutation BRCA1:c.1621C > T. Grey—breast cancer. Array—patient in the study. “BRCA1+”—patients with BRCA1 mutation. “BRCA1”—patients with no mutation of BRCA1.

3.2. Survival Analysis for Breast Cancer and Ovarian Cancer Patients

The patients with BRCA1 mutation had the worst survival in both breast cancer and ovarian cancer, compared to the patients with BRCA2 mutation and patients with no mutations. The separation in ovarian cancer among patient groups was observed to be statistically significant (log-rank test p = 0.034), while there was no statistically significant difference in survival among patients with BRCA1/2 mutation and no mutations in breast cancer (log-rank test p = 0.85) (Figure 4). Since the number of patients in each group was low, the survival analysis suggested that the trend of having a mutation of the BRCA1/2 gene or not could impact overall survival in breast cancer and ovarian cancer patients.

Figure 4

Survival analysis on breast cancer and ovarian cancer of the dataset based on patients with BRCA1/2 mutation and patients with no mutation.

3.3. Cancer Risks

The dataset showed that 8/33 (~24%) had both cancers, with the equation needing to consider both and for the additional risk for each cancer. Our analysis indicated that the individual woman’s risk increased overtime, regardless of mutation status. However, when a mutation occurred, the risk changed rapidly with BRCA1 mutation patients (middle plots) (Figure 5). In this plot, the incident rate of the cohort was used to predict the risk for each age, from 34 to 80. The rate was smoothed by a regression with a 95% confidence interval.

Figure 5

Predicted risks of breast cancer and ovarian cancer between 35 to 80 years, to a 34-year-old female given no FH of breast and/or ovarian cancer. Blue line and the shaded grey area fit the curves and 95% confidence interval. Blueline and the shaded grey area fit the curves and 95% confidence interval in smoothed line for incident rates at each age.

3.4. Breast Cancer Familial Relative Risks

Our analysis showed that there were no significant predictors for the BRCA familial relative risks. Thus, to estimate the effect of the carrier and family history, a larger cohort size and a more developed follow-up scheme are needed. The splicing-level estimation was due to splice donor damage, which introduced a high prior probability of pathogenicity (0.97) by using in Silico Prior Probability of Pathogenicity from the HCI Breast Cancer Genes Prior Probabilities website (Figure 6).

Figure 6

Probaility of Pathogenicity of BRCA1:c.4986 + 4A > T.

4. Discussion

While the presence of mutations in the BRCA1 and BRCA2 genes have been characterized in many populations in North America and Europe since 1994, the prevalence of these mutations has been, in recent years, estimated for a number of Asian populations such as China, Japan, Korea, the Philippines, Thailand, and Malaysia. In Vietnam, Ginsburg (2010) firstly found two (0.8%) BRCA1/2 gene mutations among 259 selected breast cancers in women [23]. Here, we report detailed research about BRCA1/2 gene mutations among HBOC patients in Vietnam. With two HBOC criteria in the current study, BRCA1/2 gene mutations were detected in 12 out of 33 patients. In the database of Genetic Center Myriad, USA by Frank (2002), estimating model risk of BRCA1/2 mutation, individuals with two criteria HBOC had about 4–64% risk of BRCA1/2 mutation [24].

We found no significant difference in the mean age at diagnosis amongst patients with BRCA1/2 mutation and non-mutation (t-test p = 0.391). Mean age at diagnosis was younger in BRCA1 mutation patients (48 years) compared to in BRCA2 mutation carriers (61 years). The present result was consistent with previous findings such as that ovarian cancer onset in BRCA2 mutation patients was an average 8-10 years later than in patients with BRCA1 mutation [25].

All identified mutations were checked for clinical significance in BRCA exchange. There were five nonsense mutations (c.1621C > T, c.4997dupA, c.5251C > T in BRCA1 and c.4022delC, c.5453C > A in BRCA2), where deleted, replaced, or duplicated single nucleotide were found, in addition to protein level, changing amino acid to a premature termination codon. They were predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This is why their clinical significance is determined or predicted as pathogenic. Although the BRCA2: c4022delC mutation was first found in our study, its protein level change p.Ser1341Ter is similar to the BRCA2:c4022C > A mutation, which was confirmed as pathogenic.

Four frameshift mutations (c.1016delA, c.2760_2763delACAG and c.5335delC in BRCA1 and c.4478_4481delAAAG in BRCA2), with deleted or some nucleotide, made changes in normal sequence after mutation positions. All created premature stop codons of the new reading frames were predicted to cause a truncated or absent protein, which are commonly known mechanisms for disease. All of them had pathogenic significance.

The current results found one missense mutation BRCA1: c.5068A > C, where nucleotide A was replaced by C and at the protein level changed a Lysine to a Glutamine (AAA > CAA) and did not create a premature termination codon. There are conflicting interpretations of pathogenicity between likely benign and uncertain significance. We consider it to be a variant of uncertain significance.

Only one splice-site mutation c.4986 + 4A > T in the 16th intron of BRCA1 did not directly change the encoded amino acid sequence of the BRCA1 protein, but it affected a nucleotide within the consensus splice site of the intron. Experimental studies indicated that this variant disrupted mRNA splicing and/or protein function [26]. The splicing-level estimation is due to splice donor damage, which introduces a high prior probability of pathogenicity (0.97) by using in Silico Prior Probability of Pathogenicity from the HCI Breast Cancer Genes Prior Probabilities website (Figure 6). In addition, a different nucleotide that changed at the same position (c.4986 + 4A > T) was reported as a pathogenic intronic splicing mutation in a cohort of 585 Slovak individuals with family histories of breast and ovarian cancer [17].

Depending on the location of mutation, Rebbeck et al., (2015) suggested some OCCRs and BCCR, where mutations had different risks of ovarian and breast cancer [27]. In our study, five mutations (in BRCA1 and in BRCA2) were OCCRs, which means they had higher ovarian cancer risk and lower breast cancer risk than mutations in other regions. In addition, these mutations in BCCR also lie in the domain of the BRCT of the BRCA1 gene, where protein BACH1 and other functional proteins bind to interact with protein BRCA1. Based also on analyzing the type and location of mutation, Rebbeck’s study revealed that all nonsense mutations in exon 11 of both genes had higher ovarian cancer risk and lower breast cancer risk compared to mutations at other regions and/or with other types [27].

In a recent Vietnam report of Hoang Anh Vu (2020), there were four types of pathogenic BRCA1 mutations in Vietnamese patients with ovarian cancer. Among these patients, BRCA1: c.1621C > T was present in two patients, BRCA1: c.5251C > T in four patients and BRCA1: c.5335delC in one case [4]. In a study of 200 cases of Asian origin on breast cancer patients living in the USA, three in four Vietnamese patients were identified with the mutation c.5251C > T in BRCA1 [28]. BRCA1:c.4997dupA in our study was detected in one ovarian cancer patient and one breast cancer patient, and they both had one daughter with this mutation. Whether four mutations (c.1621C > T, c.5251C > T c.4997dupA, c.5251C > T and c.5335delC) in BRCA1 gene are “founder mutations”, predisposing breast and ovarian cancer in the Vietnamese cohort, this needs to be further studied with a larger patient sample size.

Our patients were informed about the detected gene mutations, which was necessary for their oncologists to consider the use of suitable targeted therapy with PARP inhibitors. Seven in 19 relatives of patients who had BRCA1/2 gene mutations received genetic counseling for the risk of ovarian and breast cancer, in addition to screening methods and prophylactic measures according to the recommendation of the National Comprehensive Cancer Network (NCCN) [29]. We developed a risk score that took into account the risk of the patients with BRCA1/2 mutation and non-mutation and family history based on BOADICEA from the University of Cambridge (UK), contributing to further determine the HBOC risk in the future. Even though the incident rates were estimated based on a UK population, it can be gradually changed in the context of further updated studies in a Vietnamese population.

5. Conclusions

This was the first study in Vietnam to investigate mutations of BRCA1 and BRCA2 genes in breast and ovarian cancer patients with the criteria of HBOC syndrome, and to develop a risk score associated with the cohort based on carrier status and family history. BRCA1 gene mutations were present in 27.3% patients, while BRCA2 gene mutations were in 9.1% patients. Notably, two novel mutations (BRCA1: c.4997dupA and BRCA2: c.4022delC) were first documented in our study. Current findings suggested implications for the planning of a screening programme for BRCA1 and BRCA2 genes testing in breast and ovarian cancer patients and genetic screening of their relatives. Based on mutation identification, we can individualize treatment, prognosis, and follow-up more effectively, especially for Poly ADP ribose polymerase enzyme inhibitor therapy. Finally, patients with BRCA1/2 mutations without cancer should also receive early and regular cancer screening, and prophylactic measures.